Long-Term Outcomes of a Comprehensive Mobile Smoking Cessation Program With Nicotine Replacement Therapy in Adult Smokers: Pilot Randomized Controlled Trial.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

Although the related body of evidence, gathered through the conduct of randomized controlled trials (RCTs), has grown in quality and rigor, there is a need for longer-term data to assess associated smoking cessation durability.

The primary aim was to compare smoking cessation outcomes at 52 weeks in adult smokers randomized to a mobile smoking cessation program, Pivot (intervention), versus QuitGuide (control).

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

In this remote pilot RCT, cigarette smokers in the United States were recruited on the web.

Participants were offered 12 weeks of free nicotine replacement therapy (NRT).

How the Study Was Run

The design is described as randomized and pilot.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.

Data were self-reported via a web-based questionnaire with videoconference biovalidation in participants who reported 7-day point-prevalence abstinence (PPA).

Cessation outcomes included self-reported 7- and 30-day PPA, abstinence from all tobacco products, and continuous abstinence.

PPA and continuous abstinence were biovalidated using witnessed breath carbon monoxide samples.

What Was Measured

The subject headings attached to it are Pilot Projects, Smokers, Smoking, Smoking Cessation and Tobacco Use Cessation Devices.

The authors tagged it with the keywords app, biofeedback, breath sensor, carbon monoxide, digital health and digital sensor.

What This Means in Plain Language

The paper is a randomized and pilot study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (JMIR mHealth and uHealth), a journal based in Canada.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.